Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Jan 04, 2024 11:12am
134 Views
Post# 35810500

RE:RE:RE:RE:RE:RE:black out is over, but where's the beef?

RE:RE:RE:RE:RE:RE:black out is over, but where's the beef?
I feel the science is good and has great potential, but managment imo has not taken it where it should be. Think about it, They have not even continued on with the next phase of any of the goblet trials even though they all met the succesful criteria to continue on with the trials which should have been seemless. Why are they not continuing to enroll? Simple question.
And I am not rehasing old news, IT is the company which gave us a rehash and were not even upfront in regards to cash on hand when they said we had 12 months of cash but that was as of Sept. 30th, not as of today so we are now 3 months out on cash, so how are they going to run the panc trial. Big money raise and dilution again and you think this is a good thing, well I guess it is because at least they will start up the phase 3 trial (anticipation hopefully sometime in 2024). Let's just hope that the next money raise is not with a hedge fund which surprisingly the stock is now down 50% since 10 days before the pp announcement.
Kinda hard to get out at these prices and move on as most my investment was bought pre consolidation so down only about 90% and look at the track record since the consolidation in regards to shareholder value. We were at around 10 dollars and where are we now.
<< Previous
Bullboard Posts
Next >>